SCHEMBL3569360

SCHEMBL3569360

FC(F)(F)c1ccc(-c2cc(C(F)(F)F)nc(-n3cccc3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.52
ALDH1A1 P00352 5/20 0.52
KMT2A Q03164 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
HSD17B10 Q99714 6/20 0.50
MAPK1 P28482 5/20 0.50
TP53 P04637 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
MAPT P10636 2/20 0.48
ATM Q13315 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
TSHR P16473 1/20 0.47
HPGD P15428 3/20 0.46
MEN1 O00255 2/20 0.45
ALOX15 P16050 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569783 0.87 KDM4E (0.58) KDM4EALDH1A1KMT2ATDP1HSD17B10
SCHEMBL3563891 0.83 KDM4E (0.74) KDM4EALDH1A1KMT2ATDP1HSD17B10
SCHEMBL3565787 0.79 KDM4E (0.46) KDM4EALDH1A1KMT2ATDP1HSD17B10
SCHEMBL3559073 0.79 KDM4E (0.46) KDM4EALDH1A1KMT2ATDP1HSD17B10
SCHEMBL3562735 0.78 KDM4E (0.46) KDM4EALDH1A1KMT2ATDP1HSD17B10
SCHEMBL3567305 0.76 HSP90AA1 (0.48) KDM4EALDH1A1KMT2ATDP1HSD17B10
SCHEMBL3570849 0.74 PTGS2 (0.50) KDM4EALDH1A1KMT2ATDP1
SCHEMBL3564381 0.74 KDM4E (0.43) KDM4EALDH1A1KMT2ATDP1HSD17B10
Hydrochloric Acid SCHEMBL3564339 0.73 KDM4E (0.42) KDM4EALDH1A1KMT2ATDP1HSD17B10
SCHEMBL3560482 0.73 KDM4E (0.49) KDM4EALDH1A1KMT2AHSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP claimed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US claimed
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 KDM4E 2568/4885ALDH1A1 1138/4885KMT2A 2308/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 KDM4E 1276/4885ALDH1A1 3286/4885KMT2A 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.